X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com//news-release/2024/01/07/2805016/0/en/Vincerx-Pharma-Announces-Compelling-Clinical-Efficacy-of-Enitociclib-in-Combination-with-Venetoclax-and-Prednisone-in-Lymphoma.html
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration?utm_medium=email&utm_source=govdelivery#:~:text=On%20August%2011%2C%202023%2C%20the,as%20determined%20by%20an%20FDA%2D
https://www.biospace.com/article/releases/health-canada-approves-lynparza-in-combination-with-abiraterone-and-prednisone-or-prednisolone-for-patients-with-brca-mutated-metastatic-castration-resistant-prostate-cancer/
https://www.onclive.com/view/ibrutinib-plus-chemoimmunotherapy-fails-to-improve-pfs-in-pretreated-follicular-lymphoma-mzl
https://www.business-standard.com/world-news/us-fda-panel-backs-restricted-use-of-astrazeneca-s-prostate-cancer-drug-123050100632_1.html
https://www.europeanpharmaceuticalreview.com/news/180797/mhra-approves-prostate-cancer-combination-therapy/
https://www.astrazeneca.com/media-centre/press-releases/2023/overall-survival-analysis-of-the-lynparza-propel-phase-iii-trial-in-metastatic-castration-resistant-prostate-cancer.html
https://www.globenewswire.com/news-release/2023/02/16/2609811/0/en/Janssen-Presents-Updated-Data-Demonstrating-Improved-Outcomes-from-the-Use-of-Niraparib-in-Combination-with-Abiraterone-Acetate-Plus-Prednisone-as-a-First-Line-Therapy-in-Patients-.html
https://www.merck.com/news/lynparza-olaparib-in-combination-with-abiraterone-and-prednisone-or-prednisolone-approved-in-the-eu-as-treatment-for-certain-patients-with-metastatic-castration-resistant-prostate-cancer/
https://www.thepharmaletter.com/article/lynparza-combo-accepted-by-fda-for-priority-review
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-17-2022-1660735823.pdf
https://www.labiotech.eu/trends-news/genentech-lymphoma-treatment/
https://www.europeanpharmaceuticalreview.com/news/172552/improved-outcome-for-prostate-cancer-patients-in-phase-iii-propel-trial/
https://www.expresspharma.in/european-commission-approves-roches-polivy-combination-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215672
https://www.fiercepharma.com/pharma/johnson-johnson-plays-up-precision-therapy-for-zejula-s-half-successful-prostate-cancer-bid
https://www.cancernetwork.com/view/progression-free-survival-boost-noted-with-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215671
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215246
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208412
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209727
https://www.business-standard.com/article/companies/strides-pharma-science-gets-usfda-nod-for-generic-prednisone-tablets-120112300351_1.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210785
https://www.business-standard.com/article/companies/strides-pharma-gets-us-fda-nod-for-generic-anti-inflammatory-drug-120090301192_1.html#:~:text=Strides%20Pharma%20gets%20US%20FDA%20nod%20for%20generic%20anti%2Dinflammatory%20drug,-Press%20Trust%20of&text=Drug%20firm%20Strides%20Pharma%20Science,as%20an%20anti%2Dinflammatory%20medication.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213385
https://www.takeda.com/newsroom/newsreleases/2020/takeda-receives-positive-chmp-opinion-for-adcetris-brentuximab-vedotin-in-combination-with-chp-cyclophosphamide-doxorubicin-and-prednisone/
https://www.fiercepharma.com/pharma/seattle-genetics-investors-breathe-a-sigh-relief-as-adcetris-scores-30-sales-growth
https://www.pharmacompass.com/pdf/news/imprimis-njof-llc-receives-fda-warning-letter-1562735073.pdf
https://www.fiercepharma.com/pharma/j-j-s-darzalex-pads-blockbuster-sales-another-myeloma-nod-new-patients?utm_source=internal&utm_medium=rss
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211496
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2018/68782r-eng.php
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210525
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210525
https://www.businesswire.com/news/home/20181010005787/en/Celltrion-Teva-Announce-FDA-Oncologic-Drugs-Advisory
http://www.pharmatimes.com/news/janssen_bags_new_eu_approval_for_darzalex_1251100
http://www.pharmatimes.com/news/abbvie,_j_and_js_imbruvica_fails_to_target_in_b-cell_lymphoma_trial_1244036
https://www.biospace.com/article/abbvie-stock-drops-after-disappointing-clinical-trial-update/
Market Place
Share 
